Detected ·
Epicrispr Biotechnologies
$90M—
Epicrispr Biotechnologies closes a $90M oversubscribed Series C led by Octagon Capital Advisors and Janus Henderson Investors, with participation from Fidelity Investments, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, Aberdeen Investments, and Readout Capital. The funding will advance EPI-321 into pivotal studies and expand its epigenetic GEMS platform targeting FSHD.
- Website
- epicrispr.com
- Amount
- $90 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-12 04:03:56 UTC
- Signal ID
- 2f060041-eeda-45c7-93f2-f5ff0f647304
As the API returns it
{
"id": "2f060041-eeda-45c7-93f2-f5ff0f647304",
"created_at": "2026-08-12T04:03:56.067380Z",
"company_name": "Epicrispr Biotechnologies",
"company_website_url": "epicrispr.com",
"company_linkedin_url": "https://www.linkedin.com/company/epicrispr-biotechnologies",
"event_type": "funding",
"funding_amount": 90000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Epicrispr Biotechnologies closes a $90M oversubscribed Series C led by Octagon Capital Advisors and Janus Henderson Investors, with participation from Fidelity Investments, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, Aberdeen Investments, and Readout Capital. The funding will advance EPI-321 into pivotal studies and expand its epigenetic GEMS platform targeting FSHD.*"
}